210 related articles for article (PubMed ID: 28748768)
1. Allosteric Targeting of Aurora A Kinase Using Small Molecules: A Step Forward Towards Next Generation Medicines?
Panicker RC; Coyne AG; Srinivasan R
Curr Med Chem; 2019; 26(13):2234-2242. PubMed ID: 28748768
[TBL] [Abstract][Full Text] [Related]
2. Computationally-guided optimization of small-molecule inhibitors of the Aurora A kinase-TPX2 protein-protein interaction.
Cole DJ; Janecek M; Stokes JE; Rossmann M; Faver JC; McKenzie GJ; Venkitaraman AR; Hyvönen M; Spring DR; Huggins DJ; Jorgensen WL
Chem Commun (Camb); 2017 Aug; 53(67):9372-9375. PubMed ID: 28787041
[TBL] [Abstract][Full Text] [Related]
3. Identification of small molecule inhibitors of the Aurora-A/TPX2 complex.
Asteriti IA; Daidone F; Colotti G; Rinaldo S; Lavia P; Guarguaglini G; Paiardini A
Oncotarget; 2017 May; 8(19):32117-32133. PubMed ID: 28389630
[TBL] [Abstract][Full Text] [Related]
4. Structural basis for the design of allosteric inhibitors of the Aurora kinase A enzyme in the cancer chemotherapy.
de Souza VB; Kawano DF
Biochim Biophys Acta Gen Subj; 2020 Jan; 1864(1):129448. PubMed ID: 31676293
[TBL] [Abstract][Full Text] [Related]
5. Characterization of Three Druggable Hot-Spots in the Aurora-A/TPX2 Interaction Using Biochemical, Biophysical, and Fragment-Based Approaches.
McIntyre PJ; Collins PM; Vrzal L; Birchall K; Arnold LH; Mpamhanga C; Coombs PJ; Burgess SG; Richards MW; Winter A; Veverka V; Delft FV; Merritt A; Bayliss R
ACS Chem Biol; 2017 Nov; 12(11):2906-2914. PubMed ID: 29045126
[TBL] [Abstract][Full Text] [Related]
6. A TPX2 Proteomimetic Has Enhanced Affinity for Aurora-A Due to Hydrocarbon Stapling of a Helix.
Rennie YK; McIntyre PJ; Akindele T; Bayliss R; Jamieson AG
ACS Chem Biol; 2016 Dec; 11(12):3383-3390. PubMed ID: 27775325
[TBL] [Abstract][Full Text] [Related]
7. SERS and MD simulation studies of a kinase inhibitor demonstrate the emergence of a potential drug discovery tool.
Karthigeyan D; Siddhanta S; Kishore AH; Perumal SS; Ågren H; Sudevan S; Bhat AV; Balasubramanyam K; Subbegowda RK; Kundu TK; Narayana C
Proc Natl Acad Sci U S A; 2014 Jul; 111(29):10416-21. PubMed ID: 24972791
[TBL] [Abstract][Full Text] [Related]
8. Allosteric modulation of AURKA kinase activity by a small-molecule inhibitor of its protein-protein interaction with TPX2.
Janeček M; Rossmann M; Sharma P; Emery A; Huggins DJ; Stockwell SR; Stokes JE; Tan YS; Almeida EG; Hardwick B; Narvaez AJ; Hyvönen M; Spring DR; McKenzie GJ; Venkitaraman AR
Sci Rep; 2016 Jun; 6():28528. PubMed ID: 27339427
[TBL] [Abstract][Full Text] [Related]
9. Abrogation of AuroraA-TPX2 by novel natural inhibitors: molecular dynamics-based mechanistic analysis.
Gupta A; Jain R; Wahi D; Goyal S; Jamal S; Grover A
J Recept Signal Transduct Res; 2015; 35(6):626-33. PubMed ID: 26390942
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanism of Aurora A kinase autophosphorylation and its allosteric activation by TPX2.
Zorba A; Buosi V; Kutter S; Kern N; Pontiggia F; Cho YJ; Kern D
Elife; 2014 May; 3():e02667. PubMed ID: 24867643
[TBL] [Abstract][Full Text] [Related]
11. Quantitative conformational profiling of kinase inhibitors reveals origins of selectivity for Aurora kinase activation states.
Lake EW; Muretta JM; Thompson AR; Rasmussen DM; Majumdar A; Faber EB; Ruff EF; Thomas DD; Levinson NM
Proc Natl Acad Sci U S A; 2018 Dec; 115(51):E11894-E11903. PubMed ID: 30518564
[TBL] [Abstract][Full Text] [Related]
12. Aurora A kinase and its activator TPX2 are potential therapeutic targets in KRAS-induced pancreatic cancer.
Gomes-Filho SM; Dos Santos EO; Bertoldi ERM; Scalabrini LC; Heidrich V; Dazzani B; Levantini E; Reis EM; Bassères DS
Cell Oncol (Dordr); 2020 Jun; 43(3):445-460. PubMed ID: 32193808
[TBL] [Abstract][Full Text] [Related]
13. Binding of TPX2 to Aurora A alters substrate and inhibitor interactions.
Anderson K; Yang J; Koretke K; Nurse K; Calamari A; Kirkpatrick RB; Patrick D; Silva D; Tummino PJ; Copeland RA; Lai Z
Biochemistry; 2007 Sep; 46(36):10287-95. PubMed ID: 17705509
[TBL] [Abstract][Full Text] [Related]
14. Switching Aurora-A kinase on and off at an allosteric site.
Bayliss R; Burgess SG; McIntyre PJ
FEBS J; 2017 Sep; 284(18):2947-2954. PubMed ID: 28342286
[TBL] [Abstract][Full Text] [Related]
15. Discovery of N-benzylbenzamide-based allosteric inhibitors of Aurora kinase A.
Lee H; Kim E; Hwang N; Yoo J; Nam Y; Hwang I; Park JG; Park SE; Chung KS; Won Chung H; Song C; Ji MJ; Park HM; Lee IK; Lee KT; Joo Roh E; Hur W
Bioorg Med Chem; 2024 Mar; 102():117658. PubMed ID: 38460487
[TBL] [Abstract][Full Text] [Related]
16. Modulation of kinase-inhibitor interactions by auxiliary protein binding: crystallography studies on Aurora A interactions with VX-680 and with TPX2.
Zhao B; Smallwood A; Yang J; Koretke K; Nurse K; Calamari A; Kirkpatrick RB; Lai Z
Protein Sci; 2008 Oct; 17(10):1791-7. PubMed ID: 18662907
[TBL] [Abstract][Full Text] [Related]
17. Issues in interpreting the in vivo activity of Aurora-A.
Shagisultanova E; Dunbrack RL; Golemis EA
Expert Opin Ther Targets; 2015 Feb; 19(2):187-200. PubMed ID: 25384454
[TBL] [Abstract][Full Text] [Related]
18. Allosteric inhibition of Aurora-A kinase by a synthetic vNAR domain.
Burgess SG; Oleksy A; Cavazza T; Richards MW; Vernos I; Matthews D; Bayliss R
Open Biol; 2016 Jul; 6(7):. PubMed ID: 27411893
[TBL] [Abstract][Full Text] [Related]
19. Structural basis of specific binding between Aurora A and TPX2 by molecular dynamics simulations.
Cheng Y; Zhang F; Chen Q; Gao J; Cui W; Ji M; Tung CH
J Chem Inf Model; 2011 Oct; 51(10):2626-35. PubMed ID: 21919471
[TBL] [Abstract][Full Text] [Related]
20. A novel Aurora kinase A inhibitor MK-8745 predicts TPX2 as a therapeutic biomarker in non-Hodgkin lymphoma cell lines.
Chowdhury A; Chowdhury S; Tsai MY
Leuk Lymphoma; 2012 Mar; 53(3):462-71. PubMed ID: 21879811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
